Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α

Fig. 5

Frequency of myeloid-derived suppressor cells (MDSCs) in patients with CML receiving imatinib or 2nd generation TKIs. The frequency of Gr-MDSCs (a), Mo-MDSCs (b) and the ratio of Gr-MDSCs to Mo-MDSCs (c) are shown in CML patients treated with imatinib or with 2nd generation TKIs. Results are summarized as the mean ± SEM. The p values in the figure reflect statistically significant differences among study groups

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us